Find Carvedilol manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

0 DRUGS IN DEVELOPMENT

FDF DossiersDRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

JP

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

282 RELATED EXCIPIENT COMPANIES

490EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 72956-09-3, Coreg, Dilatrend, Eucardic, Kredex, Carvedilolum [latin]
Molecular Formula
C24H26N2O4
Molecular Weight
406.5  g/mol
InChI Key
OGHNVEJMJSYVRP-UHFFFAOYSA-N
FDA UNII
0K47UL67F2

Carvedilol
A carbazole and propanol derivative that acts as a non-cardioselective beta blocker and vasodilator. It has blocking activity for ALPHA 1 ADRENERGIC RECEPTORS and, at higher doses, may function as a blocker of CALCIUM CHANNELS; it also has antioxidant properties. Carvedilol is used in the treatment of HYPERTENSION; ANGINA PECTORIS; and HEART FAILURE. It can also reduce the risk of death following MYOCARDIAL INFARCTION.
Carvedilol is an alpha-Adrenergic Blocker and beta-Adrenergic Blocker. The mechanism of action of carvedilol is as an Adrenergic alpha-Antagonist and Adrenergic beta1-Antagonist and Adrenergic beta2-Antagonist.
1 2D Structure

Carvedilol

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol
2.1.2 InChI
InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3
2.1.3 InChI Key
OGHNVEJMJSYVRP-UHFFFAOYSA-N
2.1.4 Canonical SMILES
COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O
2.2 Other Identifiers
2.2.1 UNII
0K47UL67F2
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 14c-labeled Carvedilol

2. Bm 14190

3. Bm-14190

4. Bm14190

5. Carvedilol Hydrochloride

6. Carvedilol, (+)

7. Carvedilol, (+)-isomer

8. Carvedilol, (+-)-isomer

9. Carvedilol, (-)

10. Carvedilol, (-)-isomer

11. Carvedilol, (r)-isomer

12. Carvedilol, (s)-isomer

13. Carvedilol, 14c Labeled

14. Carvedilol, 14c-labeled

15. Coreg

16. Coropres

17. Dilatrend

18. Eucardic

19. Kredex

20. Querto

2.3.2 Depositor-Supplied Synonyms

1. 72956-09-3

2. Coreg

3. Dilatrend

4. Eucardic

5. Kredex

6. Carvedilolum [latin]

7. Carvedilolum

8. Querto

9. Bm 14190

10. 1-(9h-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol

11. Bm-14190

12. Dimitone

13. Artist

14. Skf 105517

15. 1-(9h-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol

16. 1-((9h-carbazol-4-yl)oxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)propan-2-ol

17. Coronis

18. Korvasan

19. Talliton

20. Dq 2466

21. Dq-2466

22. C07ag02

23. (+-)-1-(carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol

24. Chembl723

25. Nsc-758694

26. Sk&f-105517

27. Bm 14.190

28. Bm-14-190

29. Bm-14.190

30. Chebi:3441

31. 0k47ul67f2

32. [3-(9h-carbazol-4-yloxy)-2-hydroxypropyl][2-(2-methoxyphenoxy)ethyl]amine

33. 1-(9h-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol

34. Skf-105517

35. (r)-bm 14190

36. (s)-bm 14190

37. Coropress

38. Dibloc

39. R-(+)-carvedilol

40. S-(-)-carvedilol

41. 1-(9h-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol

42. Smr000449280

43. Artist (tn)

44. Coreg (tn)

45. Hsdb 7044

46. Sr-01000759289

47. Unii-0k47ul67f2

48. Mfcd00869663

49. 1-(9h-carbazol-4-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)propan-2-ol

50. Carvedilol D5

51. Eg-p042

52. Mfcd00864692

53. Carvedilol - Bio-x

54. Bm14190

55. Carvedilol [usan:usp:inn:ban:jan]

56. Spectrum_001665

57. Carvedilol [mi]

58. Carvedilol [inn]

59. Carvedilol [jan]

60. Spectrum2_001673

61. Spectrum3_001182

62. Spectrum4_000636

63. Spectrum5_001436

64. Carvedilol [hsdb]

65. Carvedilol [usan]

66. Carvedilol [vandf]

67. Carvedilol [mart.]

68. Carvedilol [usp-rs]

69. Carvedilol [who-dd]

70. Schembl22293

71. Gtpl551

72. Kbiogr_001252

73. Kbioss_002145

74. Mls000758299

75. Mls000759508

76. Mls001424092

77. Mls006011886

78. Spbio_001885

79. Carvedilol (jp17/usp/inn)

80. Carvedilol [orange Book]

81. Dtxsid8022747

82. Schembl10082334

83. Schembl13287211

84. Bdbm25759

85. Kbio2_002145

86. Kbio2_004713

87. Kbio2_007281

88. Kbio3_002323

89. Carvedilol [ep Monograph]

90. (r)-1-[(4-carbazolyl)oxy]-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol

91. Carvedilol [usp Monograph]

92. Hms2051n03

93. Hms2089b09

94. Hms2093e12

95. Hms3261e15

96. Hms3269n11

97. Hms3393n03

98. Hms3413b14

99. Hms3655o14

100. Hms3677b14

101. Hms3715d15

102. Hms3750i15

103. Hms3884e12

104. Pharmakon1600-01504257

105. Carvedilol 1.0 Mg/ml In Methanol

106. ((c)i)-carvedilol-d4(ethyl-d4)

107. Amy40801

108. Bcp23386

109. Ex-a5746

110. Hy-b0006

111. Tox21_500347

112. Bbl029064

113. Mfcd00869664

114. Nsc758694

115. S1831

116. Stk621453

117. Akos005554967

118. Carvedilol, >=98% (hplc), Solid

119. Ac-1641

120. Bcp9000493

121. Ccg-100917

122. Ccg-207952

123. Cs-1194

124. Db01136

125. Ks-1037

126. Lp00347

127. Nc00167

128. Nsc 758694

129. Sb17441

130. Sdccgsbi-0206771.p002

131. 2-propanol, 1-(9h-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-, (+-)-

132. Ncgc00167832-01

133. Ncgc00167832-02

134. Ncgc00167832-03

135. Ncgc00167832-04

136. Ncgc00167832-19

137. Ncgc00261032-01

138. Bc164291

139. Sy129821

140. Sy283162

141. Bcp0726000253

142. Sbi-0206771.p001

143. Db-055704

144. Db-057556

145. Db-057557

146. Ft-0603055

147. Ft-0603057

148. Ft-0652640

149. Ft-0664397

150. Sw197547-3

151. C06875

152. D00255

153. F19969

154. Ab00639903-07

155. Ab00639903-09

156. Ab00639903_10

157. Ab00639903_11

158. Ab00639903_12

159. 956c093

160. L001243

161. Q412534

162. Q-200801

163. Sr-01000759289-5

164. Sr-01000759289-6

165. Sr-01000759289-9

166. Brd-a10977446-001-04-8

167. Brd-a10977446-001-05-5

168. Brd-a10977446-045-01-1

169. Z2786051695

170. Carvedilol, European Pharmacopoeia (ep) Reference Standard

171. Ethyl 2-(9-(pyridin-4-ylmethyl)-9h-fluoren-9-yl)acetate

172. Carvedilol, United States Pharmacopeia (usp) Reference Standard

173. 1-(9h-carbazol-4-yloxy)-3-[2-(2-methoxy-phenoxy)-ethylamino]-propan-2-ol

174. Carvedilol, Pharmaceutical Secondary Standard; Certified Reference Material

175. (+/-)-1-carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol

176. 1-(carbazol-4-yloxy)-3-((2-(o-methoxy-phenoxy)ethyl)amino)-2-propanol

177. Carvedilol For System Suitability, European Pharmacopoeia (ep) Reference Standard

178. 107741-96-8

179. 2-propanol, 1-(9h-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-, (+/-)-

2.4 Create Date
2005-03-25
3 Chemical and Physical Properties
Molecular Weight 406.5 g/mol
Molecular Formula C24H26N2O4
XLogP34.2
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count5
Rotatable Bond Count10
Exact Mass406.18925731 g/mol
Monoisotopic Mass406.18925731 g/mol
Topological Polar Surface Area75.7 Ų
Heavy Atom Count30
Formal Charge0
Complexity508
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 6  
Drug NameCarvedilol
PubMed HealthCarvedilol (By mouth)
Drug ClassesAntianginal, Antihypertensive, Cardiovascular Agent
Drug LabelCarvedilol is a nonselective -adrenergic blocking agent with 1-blocking activity. It is ()-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. Carvedilol is a racemic mixture with the following structure:Carvedilol tablets, US...
Active IngredientCarvedilol
Dosage FormTablet
RouteOral
Strength6.25mg; 25mg; 3.125mg; 12.5mg
Market StatusPrescription
CompanyRanbaxy; Glenmark Generics; Teva; Apotex; Aurobindo Pharma; Sun Pharm Inds; Beximco Usa; Pliva Hrvatska Doo; Taro; Lupin; Zydus Pharms Usa; Dr Reddys Labs; Sandoz; Cipla; Mylan; Hikma

2 of 6  
Drug NameCoreg
PubMed HealthCarvedilol (By mouth)
Drug ClassesAntianginal, Antihypertensive, Cardiovascular Agent
Drug LabelCarvedilol is a nonselective -adrenergic blocking agent with 1-blocking activity. It is ()-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. Carvedilol is a racemic mixture with the following structure:COREG is a white, oval...
Active IngredientCarvedilol
Dosage FormTablet
RouteOral
Strength6.25mg; 25mg; 3.125mg; 12.5mg
Market StatusPrescription
CompanySmithkline Beecham

3 of 6  
Drug NameCoreg cr
PubMed HealthCarvedilol (By mouth)
Drug ClassesAntianginal, Antihypertensive, Cardiovascular Agent
Active IngredientCarvedilol phosphate
Dosage FormCapsule, extended release
RouteOral
Strength10mg; 80mg; 40mg; 20mg
Market StatusPrescription
CompanySb Pharmco

4 of 6  
Drug NameCarvedilol
PubMed HealthCarvedilol (By mouth)
Drug ClassesAntianginal, Antihypertensive, Cardiovascular Agent
Drug LabelCarvedilol is a nonselective -adrenergic blocking agent with 1-blocking activity. It is ()-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. Carvedilol is a racemic mixture with the following structure:Carvedilol tablets, US...
Active IngredientCarvedilol
Dosage FormTablet
RouteOral
Strength6.25mg; 25mg; 3.125mg; 12.5mg
Market StatusPrescription
CompanyRanbaxy; Glenmark Generics; Teva; Apotex; Aurobindo Pharma; Sun Pharm Inds; Beximco Usa; Pliva Hrvatska Doo; Taro; Lupin; Zydus Pharms Usa; Dr Reddys Labs; Sandoz; Cipla; Mylan; Hikma

5 of 6  
Drug NameCoreg
PubMed HealthCarvedilol (By mouth)
Drug ClassesAntianginal, Antihypertensive, Cardiovascular Agent
Drug LabelCarvedilol is a nonselective -adrenergic blocking agent with 1-blocking activity. It is ()-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. Carvedilol is a racemic mixture with the following structure:COREG is a white, oval...
Active IngredientCarvedilol
Dosage FormTablet
RouteOral
Strength6.25mg; 25mg; 3.125mg; 12.5mg
Market StatusPrescription
CompanySmithkline Beecham

6 of 6  
Drug NameCoreg cr
PubMed HealthCarvedilol (By mouth)
Drug ClassesAntianginal, Antihypertensive, Cardiovascular Agent
Active IngredientCarvedilol phosphate
Dosage FormCapsule, extended release
RouteOral
Strength10mg; 80mg; 40mg; 20mg
Market StatusPrescription
CompanySb Pharmco

4.2 Therapeutic Uses

Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Vasodilator Agents

National Library of Medicine's Medical Subject Headings online file (MeSH, 2009)


Carvedilol is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization. /Included in US product label/

US Natl Inst Health; DailyMed. Current Medication Information for CARVEDILOL (carvedilol) tablet (May 2011). Available from, as of September 19, 2011: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0b802a9c-332f-4ea8-bb34-75c677264654


Carvedilol is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of greater than 40 percent (with or without symptomatic heart failure). /Included in US product label/

US Natl Inst Health; DailyMed. Current Medication Information for CARVEDILOL (carvedilol) tablet (May 2011). Available from, as of September 19, 2011: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0b802a9c-332f-4ea8-bb34-75c677264654


Carvedilol is indicated for the management of essential hypertension. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. /Included in US product label/

US Natl Inst Health; DailyMed. Current Medication Information for CARVEDILOL (carvedilol) tablet (May 2011). Available from, as of September 19, 2011: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0b802a9c-332f-4ea8-bb34-75c677264654


For more Therapeutic Uses (Complete) data for CARVEDILOL (10 total), please visit the HSDB record page.


4.3 Drug Warning

Carvedilol is contraindicated in the following conditions: Bronchial asthma or related bronchospastic conditions. Deaths from status asthmaticus have been reported following single doses of carvedilol; second- or third-degree AV block; sick sinus syndrome; severe bradycardia (unless a permanent pacemaker is in place); Patients with cardiogenic shock or who have decompensated heart failure requiring the use of intravenous inotropic therapy. Such patients should first be weaned from intravenous therapy before initiating carvedilol; patients with severe hepatic impairment; patients with a history of a serious hypersensitivity reaction (eg, Stevens-Johnson syndrome, anaphylactic reaction, angioedema) to any component of this medication or other medications containing carvedilol.

US Natl Inst Health; DailyMed. Current Medication Information for CARVEDILOL (carvedilol) tablet (May 2011). Available from, as of September 19, 2011: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0b802a9c-332f-4ea8-bb34-75c677264654


Patients with coronary artery disease, who are being treated with carvedilol, should be advised against abrupt discontinuation of therapy. Severe exacerbation of angina and the occurrence of myocardial infarction and ventricular arrhythmias have been reported in angina patients following the abrupt discontinuation of therapy with beta-blockers. The last 2 complications may occur with or without preceding exacerbation of the angina pectoris. As with other beta-blockers, when discontinuation of carvedilol is planned, the patients should be carefully observed and advised to limit physical activity to a minimum. Carvedilol should be discontinued over 1 to 2 weeks whenever possible. If the angina worsens or acute coronary insufficiency develops, it is recommended that carvedilol be promptly reinstituted, at least temporarily. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue therapy with carvedilol abruptly even in patients treated only for hypertension or heart failure.

US Natl Inst Health; DailyMed. Current Medication Information for CARVEDILOL (carvedilol) tablet (May 2011). Available from, as of September 19, 2011: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0b802a9c-332f-4ea8-bb34-75c677264654


Worsening heart failure or fluid retention may occur during up-titration of carvedilol. If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes. Occasionally it is necessary to lower the carvedilol dose or temporarily discontinue it. Such episodes do not preclude subsequent successful titration of, or a favorable response to, carvedilol. In a placebo-controlled trial of patients with severe heart failure, worsening heart failure during the first 3 months was reported to a similar degree with carvedilol and with placebo. When treatment was maintai